Focus:Primary: Low-cost greenhouse production of high-quality medical cannabis in Canada. Ramping up for adult use market when legalized in Canada (October 2018), and planning significant exporting to global medical cannabis markets.
Secondary: support services including medical consultations, group therapies, and rehabilitation to veteran and first responders

Markets: StrongPrimary: Canada, US and Australia
Secondary: In 2018, increased international operations to include Germany, Italy, Malta, Lesotho, Colombia, Argentina, United Kingdom and Uruguay. Jamaica and Brazil coming in the fall. Possibly Israel.

Branding:Aphria’s current product packaging for medical cannabis is plain and simple, typical for the medical field. We do not yet see signs from Aphria of branding that would push it into the forefront of adult use brands.

Previous Project22nd Century Group

Next ProjectAuscann

Risk of Prosecution for Marijuana-Related Companies. If you are considering investing in a company that is connected to the marijuana industry, be aware that marijuana-related companies may be at risk of federal, and perhaps state, criminal prosecution. The Department of Treasury recently issued guidance noting: “[T]he Controlled Substances Act (“CSA”) makes it illegal under federal law to manufacture, distribute, or dispense marijuana. Many states impose and enforce similar prohibitions. Notwithstanding the federal ban, as of the date of this guidance, 20 states and the District of Columbia have legalized certain marijuana-related activity.”